NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT05241834 2025-09-04A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to TreatmentEli Lilly and CompanyPhase 1 Active not recruiting70 enrolled
NCT06638931 2025-05-28ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Active not recruiting28 enrolled
NCT04280081 2025-04-20LIBRETTO-321Eli Lilly and CompanyPhase 2 Active not recruiting77 enrolled 13 charts
NCT04706962 2025-04-15TH1902 in Patients With Advanced Solid TumorsTheratechnologiesPhase 1 Active not recruiting70 enrolled
NCT05620134 2024-10-15Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerSalubris Biotherapeutics IncPhase 1/2 Active not recruiting263 enrolled